Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07209371) titled 'Rifaximin Versus No Intervention for the Treatment of IgA Monoclonal Gammopathy of Undetermined Significance' on Oct. 1.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Fred Hutchinson Cancer Center
Condition:
IgA Monoclonal Gammopathy of Undetermined Significance
Intervention:
Drug: Rifaximin
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: March 1, 2026
Target Sample Size: 50
Countries of Recruitment:
United States
To know more, visit https://c...